OSR Health Clarifies Nasdaq Communication on Shareholder CVR Program

What Happened
OSR Health, Inc. (OSRH) issued a press release on August 7, 2026 (filed on Form 8‑K) clarifying statements in a prior July 31, 2026 press release about communications with The Nasdaq Stock Market LLC. The company said Nasdaq’s earlier communication was a preliminary, verbal indication limited to a technical question — specifically whether the Shareholder Loyalty Contingent Value Rights (CVR) program would trigger a mechanical adjustment to the company’s stock price (for example, an ex‑date adjustment). Nasdaq has not expressed any definitive opinion and has not approved or endorsed the CVR program. The clarification does not change the previously announced record date for the CVR program: August 14, 2026. The August 7 press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Clarification filed on Form 8‑K and issued as a press release on August 7, 2026.
• The original press release that prompted the clarification was dated July 31, 2026.
• Nasdaq’s communication was limited to a technical question about a possible mechanical/ex‑date adjustment; Nasdaq did not approve or endorse the CVR program.
• The CVR program record date remains August 14, 2026.

Why It Matters
This filing clarifies that investors should not interpret prior wording as indicating Nasdaq approval or endorsement of OSR Health’s CVR program. The communication with Nasdaq related only to a narrow technical market‑mechanics issue (potential price adjustment around an ex‑date), not substantive approval of the program. For investors, the confirmed August 14, 2026 record date remains the key date for eligibility, and the disclosure reduces ambiguity about regulatory support for the CVR program.